CytoMed Therapeutics Limited (GDTC): Earnings growth forecast for next year
CytoMed Therapeutics (GDTC) relies on CAR-T therapy, offsetting a lack of revenue through equity capital. This 12-month EPS growth projection chart reflects the market's reaction to these risks, where the value of 0.00 represents the latest figure. Stability is bolstered by the Singaporean developer's humanitarian status and the implementation of ultra-fast cold-chain logistics to maintain the viability of cell-based products during delivery.
Metric breakdowns and analytics for CytoMed (GDTC)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- company liabilities and liquidity data:
- earnings and market ratios statistics:
GDTC - Final Profit|Future Profit CytoMed Therapeutics|GDTC - Market Price to Net Income Ratio|Forward P/E Multiple w2.cytomed.sg|GDTC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple CytoMed Therapeutics|GDTC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months CytoMed Therapeutics|GDTC - Earnings per share for the trailing year|Quarterly EPS earnings growth w2.cytomed.sg|GDTC - Earnings growth in current year|Net earnings per share growth forecast for next year CytoMed Therapeutics
- total revenue and sales volume data:
Comprehensive company analysis:CytoMed Therapeutics, GDTC
Amid market volatility, it is critical for investors to differentiate speculative noise from actual asset resilience. The competitive advantage of CytoMed Therapeutics (GDTC) in developing affordable, universal T-cell therapy reduces operational risks and establishes a foundation for scaling profits. Analyzing the company's annual EPS forecast allows for an assessment of the expected added value of the share based on consensus net income projections, determining the potential for growth or the risk of portfolio stagnation.
Competitors of CytoMed Therapeutics
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Candel Therapeutics, Inc. (CADL)|Earnings growth forecast for next year Accuray (ARAY)|Net earnings per share growth forecast for next year SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|HURA: Net earnings per share growth forecast for next year|TARA (Protara) - Expected earnings per share growth for next year|Fate Therapeutics, Inc. - Expected earnings per share trend next year|WHWK (aadibio.com) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Champions Oncology (CSBR)|XBiotech - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Consensus forecast of earnings per share growth for next year OS Therapies (OSTX)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics|ANL (adlainortye.com) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Veru Pharma|TPST (Tempest Therapeutics Inc) - Earnings growth forecast for next year|Xilio Therapeutics, Inc. (XLO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Enochian BioSciences (RENB)|MURA: Net earnings per share change forecast for next year|Earnings growth forecast for next year KAPA (kairospharma.com)|Consensus forecast of earnings per share growth for next year OnKure (OKUR)|Curis - Earnings growth forecast for next year|APLM: Net earnings per share growth forecast for next year|Tharimmune (THAR) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed Inc.|GNPX (Genprex Inc) - Earnings growth forecast for next year|Calidi Biotherapeutics (CLDI) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year SBFM|Net earnings per share growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|Earnings growth forecast for next year SLRX (salariuspharma.com)|PPBT - Expected earnings per share growth for next year|AONC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year BGNE (BeOne Medicines)|CKPT: Earnings growth forecast for next year|Elevation Oncology Inc. (ELEV) - Earnings growth forecast for next year|ICAD (iCAD) - Earnings growth forecast for next year|Earnings growth forecast for next year ikenaoncology.com|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year Viracta Therapeutics Inc. (VIRX)|Net earnings per share growth forecast for next year MorphoSys Inc MOR|Expected earnings per share trend next year NAYA|AAPGV: Expected earnings per share growth for next year
